SCHEMBL1635864

SCHEMBL1635864

COc1ccc(CS)cc1SP(=O)(OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.43
SMPD1 P17405 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.38
APP P05067 1/20 0.37
CETP P11597 3/20 0.36
RXRA P19793 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1636241 0.84 IDO1 (0.34) SMN1; SMN2KDM4E
SCHEMBL1635474 0.83 IDO1 (0.37) FOLH1HPGDSMN1; SMN2KDM4EATM
SCHEMBL1634310 0.80 SMPD1 (0.39) SMPD1HDAC1HDAC8HDAC6NPC1
SCHEMBL1635284 0.79 SMPD1 (0.39) SMPD1HDAC1HDAC8HDAC6NPC1
SCHEMBL1634824 0.78 PLK1 (0.52) HDAC1HDAC8HDAC6SMN1; SMN2KDM4E
SCHEMBL1634215 0.77 IDO1 (0.37) FOLH1HDAC1HDAC6NPC1TSHR
SCHEMBL1635884 0.77 SMPD1 (0.47) FOLH1SMPD1HDAC1HDAC8HDAC6
SCHEMBL1634932 0.77 NPC1 (0.49) SMPD1HDAC1HDAC8HDAC6NPC1
SCHEMBL1636871 0.75 TAS2R14 (0.35) SMPD1HDAC1HDAC8HDAC6APP
SCHEMBL1634504 0.74 L3MBTL1 (0.47) SMN1; SMN2TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138832-A1 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University - Of The Commonwealth System of Higher Education (US) 2017-03-08 EP disclosed
EP-1740530-B1 SUBSTITUTED PHENOXY- AND PHENYLTHIO-DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2016-09-28 EP disclosed
US-7932242-B2 Anticancer agents; radiation and chemical resistance TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-04-26 US disclosed
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders PCNA, MKI67, TP53 FOLH1 1358/4885SMPD1 2609/4885HDAC1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.